Iron and neurodegeneration in the multiple sclerosis brain

Annals of Neurology

Volumn 74, Issue 6, 2013, Pages 848-861

  Hametner, Simon ^a   Wimmer, Isabella ^a   Haider, Lukas ^a   Pfeifenbring, Sabine ^b   Brück, Wolfgang ^b   Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; FERRITIN; HEPHAESTIN; IRON; MYELIN;

ADULT; AGED; ARTICLE; ASTROCYTE; BIOACCUMULATION; BRAIN TISSUE; CELL COUNTING; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DISEASE DURATION; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRON HISTOCHEMISTRY; IRON KINETICS; IRON TRANSPORT; MACROPHAGE; MALE; MICROARRAY ANALYSIS; MICROGLIA; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RESPIRATORY BURST; UPREGULATION; VERY ELDERLY; WHITE MATTER;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN; CELL COUNT; CERULOPLASMIN; CHILD; FEMALE; FERRITINS; HUMANS; IRON; IRON-BINDING PROTEINS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; YOUNG ADULT;

EID: 84892915145     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23974     Document Type: Article

References (54)

1. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132 (pt 5): 1175-1189.
2. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366: 1000-1009.
3. Lassmann H, van Horssen J, Mahad D,. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647-656.
4. Khalil M, Langkammer C, Ropele S, et al. Determinants of brain iron in multiple sclerosis: a quantitative 3T MRI study. Neurology 2011; 77: 1691-1697.
5. Singh AV, Zamboni P,. Anomalous venous blood flow and iron deposition in multiple sclerosis. J Cereb Blood Flow Metab 2009; 29: 1867-1878.
6. Hallgren B, Sourander P,. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3: 41-51.
7. Confavreux C, Vukusic S, Moreau T, Adeleine P,. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
8. Connor JR, Menzies SL,. Cellular management of iron in the brain. J Neurol Sci 1995; 134 (suppl): 33-44.
9. Todorich B, Pasquini JM, Garcia CI, et al. Oligodendrocytes and myelination: the role of iron. Glia 2009; 57: 467-478.
10. Kell DB,. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009; 2: 2.
11. Roede JR, Jones DP,. Reactive species and mitochondrial dysfunction: mechanistic significance of 4-hydroxynonenal. Environ Mol Mutagen 2010; 51: 380-390.
12. Murphy MP,. How mitochondria produce reactive oxygen species. Biochem J 2009; 417: 1-13.
13. Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012; 135 (pt 3): 886-899.
14. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 2011; 69: 481-492.
15. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-489.
16. Ziabreva I, Campbell G, Rist J, et al. Injury and differentiation following inhibition of mitochondrial respiratory chain complex IV in rat oligodendrocytes. Glia 2010; 58: 1827-1837.
17. Craelius W, Migdal MW, Luessenhop CP, et al. Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 1982; 106: 397-399.
18. Adams CW,. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry 1988; 51: 260-265.
19. LeVine SM,. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 1997; 760: 298-303.
20. Breitschopf H, Suchanek G, Gould RM, et al. In situ hybridization with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain. Acta Neuropathol 1992; 84: 581-587.
21. Barnett MH, Prineas JW,. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-468.
22. Marik C, Felts PA, Bauer J, et al. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 2007; 130 (pt 11): 2800-2815.
23. Fischer MT, Wimmer I, Hoftberger R, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 2013; 136 (pt 6): 1799-1815.
24. Brück W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38: 788-796.
25. Meguro R, Asano Y, Odagiri S, et al. Nonheme-iron histochemistry for light and electron microscopy: a historical, theoretical and technical review. Arch Histol Cytol 2007; 70: 1-19.
26. Bagnato F, Hametner S, Yao B, et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 tesla. Brain 2011; 134 (pt 12): 3602-3615.
27. Bauer J, Elger CE, Hans VH, et al. Astrocytes are a specific immunological target in Rasmussen's encephalitis. Ann Neurol 2007; 62: 67-80.
28. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134 (pt 7): 1914-1924.
29. Lassmann H,. The architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis [review]. Neuropathol Applied Neurobiol 2011; 37: 698-710.
30. Schulz K, Vulpe CD, Harris LZ, David S,. Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. J Neurosci 2011; 31: 13301-13311.
31. Mahad D, Ziabreva I, Lassmann H, Turnbull D,. Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008; 131 (pt 7): 1722-1735.
32. Mews I, Bergmann M, Bunkowski S, et al. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998; 4: 55-62.
33. Streit WJ, Braak H, Xue QS, Bechmann I,. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009; 118: 475-485.
34. Lopes KO, Sparks DL, Streit WJ,. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 2008; 56: 1048-1060.
35. Simmons DA, Casale M, Alcon B, et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 2007; 55: 1074-1084.
36. Paling D, Tozer D, Wheeler-Kingshott C, et al. Reduced R2′ in multiple sclerosis normal appearing white matter and lesions may reflect decreased myelin and iron content. J Neurol Neurosurg Psychiatry 2012; 83: 785-792.
37. Rathore KI, Redensek A, David S,. Iron homeostasis in astrocytes and microglia is differentially regulated by TNF-alpha and TGF-beta1. Glia 2012; 60: 738-750.
38. Zhang X, Haaf M, Todorich B, et al. Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia 2005; 52: 199-208.
39. Zhang X, Surguladze N, Slagle-Webb B, et al. Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia 2006; 54: 795-804.
40. van Horssen J, Drexhage JA, Flor T, et al. Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med 2010; 49: 1283-1289.
41. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-1107.
42. Gray E, Thomas TL, Betmouni S, et al. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett 2008; 444: 195-198.
43. Liu Y, Hao W, Letiembre M, et al. Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. J Neurosci 2006; 26: 12904-12913.
44. Jomova K, Valko M,. Advances in metal-induced oxidative stress and human disease. Toxicology 2011; 283: 65-87.
45. Nunez MT, Urrutia P, Mena N, et al. Iron toxicity in neurodegeneration. Biometals 2012; 25: 761-776.
46. Williams R, Buchheit CL, Berman NE, LeVine SM,. Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem 2012; 120: 7-25.
47. Pitt D, Boster A, Pei W, et al. Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol 2010; 67: 812-818.
48. Rathnasamy G, Ling EA, Kaur C,. Iron and iron regulatory proteins in amoeboid microglial cells are linked to oligodendrocyte death in hypoxic neonatal rat periventricular white matter through production of proinflammatory cytokines and reactive oxygen/nitrogen species. J Neurosci 2011; 31: 17982-17995.
49. Aboul-Enein F, Rauschka H, Kornek B, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003; 62: 25-33.
50. Trapp BD, Stys PK,. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-291.
51. van Zwam M, Huizinga R, Melief MJ, et al. Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med (Berl) 2009; 87: 273-286.
52. Oude Engberink RD, Blezer EL, Dijkstra CD, et al. Dynamics and fate of USPIO in the central nervous system in experimental autoimmune encephalomyelitis. NMR Biomed 2010; 23: 1087-1096.
53. Schonberg DL, Goldstein EZ, Sahinkaya FR, et al. Ferritin stimulates oligodendrocyte genesis in the adult spinal cord and can be transferred from macrophages to NG2 cells in vivo. J Neurosci 2012; 32: 5374-5384.
54. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL,. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10: 325-335.